Reocclusion: The flip side of coronary thrombolysis

Since the introduction of thrombolytic therapy for acute myocardial infarction, the incidence of coronary artery reocclusion has been intensively studied. Also, the prediction and diagnosis of reocclusion by angiographic and clinical variables, as well its invasive and pharmacologic prevention, have...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 1996-03, Vol.27 (4), p.766-773
Hauptverfasser: Verheugt, Freek W.A., Meijer, Albert, Lagrand, Wim K., van Eenige, Machiel J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 773
container_issue 4
container_start_page 766
container_title Journal of the American College of Cardiology
container_volume 27
creator Verheugt, Freek W.A.
Meijer, Albert
Lagrand, Wim K.
van Eenige, Machiel J.
description Since the introduction of thrombolytic therapy for acute myocardial infarction, the incidence of coronary artery reocclusion has been intensively studied. Also, the prediction and diagnosis of reocclusion by angiographic and clinical variables, as well its invasive and pharmacologic prevention, have gained much attention. By angiographic definition, reocclusion requires three angiographic observations: one with an occluded artery, one with a reperfused artery and a third for the assessment of subsequent occlusion (true reocclusion). Since the introduction of early intravenous reperfusion therapy, most studies use only two angiograms: one with a patent and one with a nonpatent infarct-related artery. A search for all published reocclusion studies revealed 61 studies (6,061 patients) with at least two angiograms. The median time interval between the first angiogram after thrombosis and the second was 16 days (range 0.1 to 365). Reocclusion was observed in 666 (11%) of 6,061 cases. Interestingly, the 28 true reocclusion studies showed an incidence of reocclusion of 16 ± 10% (mean ± SD), and the 33 studies with only two angiograms 10 ± 8% (p = 0.04), suggesting that proven initial occlusion of the infarct-related artery is a risk factor for reocclusion after successful thrombolysis. The other predictors for reocclusion are probably severity of residual stenosis of the infarct-related artery after thrombolysis and perhaps the flow state after lysis. Reocclusion is most frequently seen in the early weeks after thrombolysis. The clinical course in patients with reocclusion is more complicated than in those without complication. Left ventricular contractile recovery after thrombolysis is hampered by reocclusion. Routine invasive strategies have not been proven effective against reocclusion. In the prevention of reocclusion, both antiplatelet and antithrombin strategies have been tested, including hirudin and hirulog, but the safety of these agents in thrombolysis is still questionable. Thus, reocclusion after thrombolysis is an early phenomenon and is more frequent after proven initial occlusion of the infarct-related artery. Reocclusion can be predicted by angiography after thrombolysis. Because reocclusion is detrimental, strategies to prevent it should be developed and carried out after thrombolytic therapy for acute myocardial infarction as soon as they are deemed safe.
doi_str_mv 10.1016/0735-1097(95)00492-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78015278</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0735109795004920</els_id><sourcerecordid>78015278</sourcerecordid><originalsourceid>FETCH-LOGICAL-c561t-cd438f4ce145480123f5fbb28b51f0a0f1ad1985310e2d444ac0de8121b34d573</originalsourceid><addsrcrecordid>eNp9kE1LLDEQRYM88Y2j_8AHvRDRRWtVJ-lOuxBE_AJBEF2HdFLBSE9nTGYE_709zjDLt6rFPfdSHMaOEM4RsL6AhssSoW1OW3kGINqqhB02QSlVyWXb_GGTLfKX7ef8AQC1wnaP7akaeQ04YfyForX9Moc4XBav71T4PsyLHBwV0Rc2pjiY9F0s3lOcdbH_ziEfsF1v-kyHmztlb3e3rzcP5dPz_ePN9VNpZY2L0jrBlReWUEihACvupe-6SnUSPRjwaBy2SnIEqpwQwlhwpLDCjgsnGz5lJ-vdeYqfS8oLPQvZUt-bgeIy62YclVWjRlCsQZtizom8nqcwG9_WCHrlSq9E6JUI3Ur960rDWPu32V92M3Lb0kbOmB9vcpOt6X0ygw15i3HgquVixK7WGI0uvgIlnW2gwZILiexCuxj-_8cPWqaDiQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78015278</pqid></control><display><type>article</type><title>Reocclusion: The flip side of coronary thrombolysis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Verheugt, Freek W.A. ; Meijer, Albert ; Lagrand, Wim K. ; van Eenige, Machiel J.</creator><creatorcontrib>Verheugt, Freek W.A. ; Meijer, Albert ; Lagrand, Wim K. ; van Eenige, Machiel J.</creatorcontrib><description>Since the introduction of thrombolytic therapy for acute myocardial infarction, the incidence of coronary artery reocclusion has been intensively studied. Also, the prediction and diagnosis of reocclusion by angiographic and clinical variables, as well its invasive and pharmacologic prevention, have gained much attention. By angiographic definition, reocclusion requires three angiographic observations: one with an occluded artery, one with a reperfused artery and a third for the assessment of subsequent occlusion (true reocclusion). Since the introduction of early intravenous reperfusion therapy, most studies use only two angiograms: one with a patent and one with a nonpatent infarct-related artery. A search for all published reocclusion studies revealed 61 studies (6,061 patients) with at least two angiograms. The median time interval between the first angiogram after thrombosis and the second was 16 days (range 0.1 to 365). Reocclusion was observed in 666 (11%) of 6,061 cases. Interestingly, the 28 true reocclusion studies showed an incidence of reocclusion of 16 ± 10% (mean ± SD), and the 33 studies with only two angiograms 10 ± 8% (p = 0.04), suggesting that proven initial occlusion of the infarct-related artery is a risk factor for reocclusion after successful thrombolysis. The other predictors for reocclusion are probably severity of residual stenosis of the infarct-related artery after thrombolysis and perhaps the flow state after lysis. Reocclusion is most frequently seen in the early weeks after thrombolysis. The clinical course in patients with reocclusion is more complicated than in those without complication. Left ventricular contractile recovery after thrombolysis is hampered by reocclusion. Routine invasive strategies have not been proven effective against reocclusion. In the prevention of reocclusion, both antiplatelet and antithrombin strategies have been tested, including hirudin and hirulog, but the safety of these agents in thrombolysis is still questionable. Thus, reocclusion after thrombolysis is an early phenomenon and is more frequent after proven initial occlusion of the infarct-related artery. Reocclusion can be predicted by angiography after thrombolysis. Because reocclusion is detrimental, strategies to prevent it should be developed and carried out after thrombolytic therapy for acute myocardial infarction as soon as they are deemed safe.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/0735-1097(95)00492-0</identifier><identifier>PMID: 8613601</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Antithrombins - therapeutic use ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Constriction, Pathologic ; Coronary Angiography ; Fibrinolytic Agents - therapeutic use ; Heparin - therapeutic use ; Hirudin Therapy ; Hirudins - analogs &amp; derivatives ; Humans ; Incidence ; Medical sciences ; Myocardial Infarction - drug therapy ; Myocardial Infarction - epidemiology ; Myocardial Infarction - prevention &amp; control ; Peptide Fragments - therapeutic use ; Pharmacology. Drug treatments ; Prognosis ; Recombinant Proteins - therapeutic use ; Recurrence ; Thrombolytic Therapy</subject><ispartof>Journal of the American College of Cardiology, 1996-03, Vol.27 (4), p.766-773</ispartof><rights>1996</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c561t-cd438f4ce145480123f5fbb28b51f0a0f1ad1985310e2d444ac0de8121b34d573</citedby><cites>FETCH-LOGICAL-c561t-cd438f4ce145480123f5fbb28b51f0a0f1ad1985310e2d444ac0de8121b34d573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0735-1097(95)00492-0$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3038934$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8613601$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verheugt, Freek W.A.</creatorcontrib><creatorcontrib>Meijer, Albert</creatorcontrib><creatorcontrib>Lagrand, Wim K.</creatorcontrib><creatorcontrib>van Eenige, Machiel J.</creatorcontrib><title>Reocclusion: The flip side of coronary thrombolysis</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>Since the introduction of thrombolytic therapy for acute myocardial infarction, the incidence of coronary artery reocclusion has been intensively studied. Also, the prediction and diagnosis of reocclusion by angiographic and clinical variables, as well its invasive and pharmacologic prevention, have gained much attention. By angiographic definition, reocclusion requires three angiographic observations: one with an occluded artery, one with a reperfused artery and a third for the assessment of subsequent occlusion (true reocclusion). Since the introduction of early intravenous reperfusion therapy, most studies use only two angiograms: one with a patent and one with a nonpatent infarct-related artery. A search for all published reocclusion studies revealed 61 studies (6,061 patients) with at least two angiograms. The median time interval between the first angiogram after thrombosis and the second was 16 days (range 0.1 to 365). Reocclusion was observed in 666 (11%) of 6,061 cases. Interestingly, the 28 true reocclusion studies showed an incidence of reocclusion of 16 ± 10% (mean ± SD), and the 33 studies with only two angiograms 10 ± 8% (p = 0.04), suggesting that proven initial occlusion of the infarct-related artery is a risk factor for reocclusion after successful thrombolysis. The other predictors for reocclusion are probably severity of residual stenosis of the infarct-related artery after thrombolysis and perhaps the flow state after lysis. Reocclusion is most frequently seen in the early weeks after thrombolysis. The clinical course in patients with reocclusion is more complicated than in those without complication. Left ventricular contractile recovery after thrombolysis is hampered by reocclusion. Routine invasive strategies have not been proven effective against reocclusion. In the prevention of reocclusion, both antiplatelet and antithrombin strategies have been tested, including hirudin and hirulog, but the safety of these agents in thrombolysis is still questionable. Thus, reocclusion after thrombolysis is an early phenomenon and is more frequent after proven initial occlusion of the infarct-related artery. Reocclusion can be predicted by angiography after thrombolysis. Because reocclusion is detrimental, strategies to prevent it should be developed and carried out after thrombolytic therapy for acute myocardial infarction as soon as they are deemed safe.</description><subject>Antithrombins - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Constriction, Pathologic</subject><subject>Coronary Angiography</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Heparin - therapeutic use</subject><subject>Hirudin Therapy</subject><subject>Hirudins - analogs &amp; derivatives</subject><subject>Humans</subject><subject>Incidence</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - epidemiology</subject><subject>Myocardial Infarction - prevention &amp; control</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Recurrence</subject><subject>Thrombolytic Therapy</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LLDEQRYM88Y2j_8AHvRDRRWtVJ-lOuxBE_AJBEF2HdFLBSE9nTGYE_709zjDLt6rFPfdSHMaOEM4RsL6AhssSoW1OW3kGINqqhB02QSlVyWXb_GGTLfKX7ef8AQC1wnaP7akaeQ04YfyForX9Moc4XBav71T4PsyLHBwV0Rc2pjiY9F0s3lOcdbH_ziEfsF1v-kyHmztlb3e3rzcP5dPz_ePN9VNpZY2L0jrBlReWUEihACvupe-6SnUSPRjwaBy2SnIEqpwQwlhwpLDCjgsnGz5lJ-vdeYqfS8oLPQvZUt-bgeIy62YclVWjRlCsQZtizom8nqcwG9_WCHrlSq9E6JUI3Ur960rDWPu32V92M3Lb0kbOmB9vcpOt6X0ygw15i3HgquVixK7WGI0uvgIlnW2gwZILiexCuxj-_8cPWqaDiQ</recordid><startdate>19960315</startdate><enddate>19960315</enddate><creator>Verheugt, Freek W.A.</creator><creator>Meijer, Albert</creator><creator>Lagrand, Wim K.</creator><creator>van Eenige, Machiel J.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960315</creationdate><title>Reocclusion: The flip side of coronary thrombolysis</title><author>Verheugt, Freek W.A. ; Meijer, Albert ; Lagrand, Wim K. ; van Eenige, Machiel J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c561t-cd438f4ce145480123f5fbb28b51f0a0f1ad1985310e2d444ac0de8121b34d573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antithrombins - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Constriction, Pathologic</topic><topic>Coronary Angiography</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Heparin - therapeutic use</topic><topic>Hirudin Therapy</topic><topic>Hirudins - analogs &amp; derivatives</topic><topic>Humans</topic><topic>Incidence</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - epidemiology</topic><topic>Myocardial Infarction - prevention &amp; control</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Recurrence</topic><topic>Thrombolytic Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verheugt, Freek W.A.</creatorcontrib><creatorcontrib>Meijer, Albert</creatorcontrib><creatorcontrib>Lagrand, Wim K.</creatorcontrib><creatorcontrib>van Eenige, Machiel J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verheugt, Freek W.A.</au><au>Meijer, Albert</au><au>Lagrand, Wim K.</au><au>van Eenige, Machiel J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reocclusion: The flip side of coronary thrombolysis</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1996-03-15</date><risdate>1996</risdate><volume>27</volume><issue>4</issue><spage>766</spage><epage>773</epage><pages>766-773</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>Since the introduction of thrombolytic therapy for acute myocardial infarction, the incidence of coronary artery reocclusion has been intensively studied. Also, the prediction and diagnosis of reocclusion by angiographic and clinical variables, as well its invasive and pharmacologic prevention, have gained much attention. By angiographic definition, reocclusion requires three angiographic observations: one with an occluded artery, one with a reperfused artery and a third for the assessment of subsequent occlusion (true reocclusion). Since the introduction of early intravenous reperfusion therapy, most studies use only two angiograms: one with a patent and one with a nonpatent infarct-related artery. A search for all published reocclusion studies revealed 61 studies (6,061 patients) with at least two angiograms. The median time interval between the first angiogram after thrombosis and the second was 16 days (range 0.1 to 365). Reocclusion was observed in 666 (11%) of 6,061 cases. Interestingly, the 28 true reocclusion studies showed an incidence of reocclusion of 16 ± 10% (mean ± SD), and the 33 studies with only two angiograms 10 ± 8% (p = 0.04), suggesting that proven initial occlusion of the infarct-related artery is a risk factor for reocclusion after successful thrombolysis. The other predictors for reocclusion are probably severity of residual stenosis of the infarct-related artery after thrombolysis and perhaps the flow state after lysis. Reocclusion is most frequently seen in the early weeks after thrombolysis. The clinical course in patients with reocclusion is more complicated than in those without complication. Left ventricular contractile recovery after thrombolysis is hampered by reocclusion. Routine invasive strategies have not been proven effective against reocclusion. In the prevention of reocclusion, both antiplatelet and antithrombin strategies have been tested, including hirudin and hirulog, but the safety of these agents in thrombolysis is still questionable. Thus, reocclusion after thrombolysis is an early phenomenon and is more frequent after proven initial occlusion of the infarct-related artery. Reocclusion can be predicted by angiography after thrombolysis. Because reocclusion is detrimental, strategies to prevent it should be developed and carried out after thrombolytic therapy for acute myocardial infarction as soon as they are deemed safe.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>8613601</pmid><doi>10.1016/0735-1097(95)00492-0</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 1996-03, Vol.27 (4), p.766-773
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_miscellaneous_78015278
source MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Antithrombins - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Constriction, Pathologic
Coronary Angiography
Fibrinolytic Agents - therapeutic use
Heparin - therapeutic use
Hirudin Therapy
Hirudins - analogs & derivatives
Humans
Incidence
Medical sciences
Myocardial Infarction - drug therapy
Myocardial Infarction - epidemiology
Myocardial Infarction - prevention & control
Peptide Fragments - therapeutic use
Pharmacology. Drug treatments
Prognosis
Recombinant Proteins - therapeutic use
Recurrence
Thrombolytic Therapy
title Reocclusion: The flip side of coronary thrombolysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T17%3A26%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reocclusion:%20The%20flip%20side%20of%20coronary%20thrombolysis&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Verheugt,%20Freek%20W.A.&rft.date=1996-03-15&rft.volume=27&rft.issue=4&rft.spage=766&rft.epage=773&rft.pages=766-773&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/0735-1097(95)00492-0&rft_dat=%3Cproquest_cross%3E78015278%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78015278&rft_id=info:pmid/8613601&rft_els_id=0735109795004920&rfr_iscdi=true